Goldman Sachs Maintains Buy on Calumet Specialty Prods, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Neil Mehta maintains a Buy rating on Calumet Specialty Products (NASDAQ:CLMT) but lowers the price target from $19 to $17.

March 21, 2024 | 3:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Calumet Specialty Products but lowers the price target from $19 to $17.
While the maintenance of a Buy rating by Goldman Sachs indicates continued confidence in Calumet Specialty Products' fundamentals, the reduction in the price target could suggest a tempered outlook on the stock's short-term price performance. Investors might view this adjustment as a sign of potential headwinds or a recalibration of expectations, possibly leading to mixed reactions in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100